Assertio (ASRT) Projected to Post Quarterly Earnings on Wednesday

Assertio (NASDAQ:ASRT) is anticipated to issue its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect Assertio to post earnings of ($3.05) per share and revenue of $6.1990 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 16, 2026 at 4:30 PM ET.

Assertio Price Performance

Shares of NASDAQ:ASRT opened at $11.90 on Wednesday. The stock has a market capitalization of $76.40 million, a P/E ratio of -2.56 and a beta of 0.73. The business has a 50-day moving average of $11.15 and a two-hundred day moving average of $11.78. Assertio has a fifty-two week low of $7.65 and a fifty-two week high of $15.15. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.58 and a quick ratio of 1.43.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Nantahala Capital Management LLC raised its position in shares of Assertio by 4.4% during the second quarter. Nantahala Capital Management LLC now owns 8,810,073 shares of the company’s stock valued at $5,649,000 after buying an additional 370,311 shares during the last quarter. Vanguard Group Inc. raised its holdings in Assertio by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,425,543 shares of the company’s stock valued at $3,899,000 after acquiring an additional 41,332 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Assertio in the 3rd quarter worth approximately $26,000. Perritt Capital Management Inc lifted its position in shares of Assertio by 51.6% in the 3rd quarter. Perritt Capital Management Inc now owns 350,316 shares of the company’s stock worth $309,000 after acquiring an additional 119,281 shares during the period. Finally, Edgewood Management LLC acquired a new stake in shares of Assertio during the 4th quarter worth approximately $975,000. Institutional investors own 48.96% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ASRT shares. Zacks Research upgraded Assertio from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 30th. HC Wainwright reissued a “buy” rating and issued a $35.00 price target (up from $3.00) on shares of Assertio in a research report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assertio in a report on Wednesday, January 21st. Finally, Wall Street Zen upgraded shares of Assertio to a “buy” rating in a report on Saturday, November 22nd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.63.

About Assertio

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.